Cited 8 times in
Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.date.accessioned | 2019-11-26T00:56:47Z | - |
dc.date.available | 2019-11-26T00:56:47Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/172601 | - |
dc.description.abstract | A phase II trial of a novel platinum analog, SKI 2053R, was performed in patients with previously untreated extensive-stage disease (ED) small-cell lung cancer (SCLC). SKI 2053R was administered at the dose of 400 mg/m2 every 3 to 4 weeks as a 1-h infusion. After the first cycle, the dose was escalated to 440 mg/m2 based on toxicity. Thirty-eight patients (31 male) were enrolled between June 1995 and August 1997. The median age was 61 years (range, 36-70 years). Six of 37 evaluable patients achieved a partial response (16.2%; 95% confidence interval [CI], 4.4-28.0%). The durations of response were 1.1, 1.5, 1.7, 1.9, 3.4, and 4.6 months. The estimated median survival time was 7.4 months (95% CI, 5.1-9.7 months). Grade 3 or 4 toxicities were not observed. Grade 1 to 2 leukopenia, anemia, and thrombocytopenia were seen in 5 of 68 cycles, 16 of 68, and 2 of 68, respectively. Nonhematologic toxicities included grade 1 to 2 nausea or vomiting (30 of 68 cycles), nephrotoxicity (27 of 68), and hepatotoxicity (13 of 68). SKI 2053R showed a modest antitumor activity with limited toxicities in patients with ED SCLC. Further clinical trials are warranted in SCLC with a higher dose of SKI 2053R. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/chemistry | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Small Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Small Cell/mortality | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematologic Diseases/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea/epidemiology | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Malonates/chemistry | - |
dc.subject.MESH | Malonates/therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nausea/diagnosis | - |
dc.subject.MESH | Organoplatinum Compounds/chemistry | - |
dc.subject.MESH | Organoplatinum Compounds/therapeutic use* | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Zang, Dae Young | - |
dc.contributor.googleauthor | Lee, Kyoo Hyung | - |
dc.contributor.googleauthor | Lee, Jung Shin | - |
dc.contributor.googleauthor | Lee, Je Hwan | - |
dc.contributor.googleauthor | Kim, Woo Kun | - |
dc.contributor.googleauthor | Kim, Sang-Hee | - |
dc.contributor.googleauthor | Kim, Won Dong | - |
dc.contributor.googleauthor | Kim, Dong Soon | - |
dc.contributor.googleauthor | Kim, Joo Hang | - |
dc.contributor.googleauthor | Kim, Byung Soo | - |
dc.contributor.googleauthor | Cho, Yong-Baik | - |
dc.contributor.googleauthor | Kim, Dae-Kee | - |
dc.contributor.googleauthor | Kim, Key H | - |
dc.identifier.doi | 10.1097/00000421-199910000-00015 | - |
dc.contributor.localId | A00945 | - |
dc.relation.journalcode | J00075 | - |
dc.identifier.eissn | 1537-453X | - |
dc.identifier.pmid | 10521066 | - |
dc.identifier.url | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-199910000-00015&LSLINK=80&D=ovft | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 495 | - |
dc.citation.endPage | 498 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.22(5) : 495-498, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.